Winship Institute of Emory University, 1365 Clifton Rd NE, Suite 4400, Atlanta, GA, USA.
Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 N. St. Clair Street, Suite 850, Chicago, IL, 60611, USA.
Curr Oncol Rep. 2020 Apr 16;22(5):44. doi: 10.1007/s11912-020-00902-1.
Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas with inferior prognosis compared with their B cell counterparts characterized by frequent relapses, resulting in a median 5-year survival of approximately 30%. Their diverse clinicopathologic features challenge existing treatment paradigms that treat all patients uniformly. Here we review recent advances in the treatment of these diseases.
While current treatment still relies largely on combination chemotherapy, the introduction of more effective novel and targeted therapies has improved outcomes in certain subtypes. Increasing understanding of the underlying biology of PTCL has prompted further subclassification by genetic and molecular subgroups. Overall, the most significant advances in PTCL management have resulted from improved understanding and classification of the biology of PTCL. Ongoing development of subtype-specific targeted therapies will be essential to improve long-term outcomes of patients with these diseases.
外周 T 细胞淋巴瘤（PTCL）是一组异质性非霍奇金淋巴瘤，与 B 细胞淋巴瘤相比，其预后较差，其特征为频繁复发，导致中位 5 年生存率约为 30%。它们多样化的临床病理特征对现有的治疗模式提出了挑战，这些治疗模式对所有患者都是统一的。在这里，我们回顾了这些疾病治疗的最新进展。
虽然目前的治疗仍然主要依赖于联合化疗，但新型和靶向治疗的引入已改善了某些亚型的疗效。对 PTCL 基础生物学的认识不断加深，促使根据遗传和分子亚群进一步进行分类。总的来说，PTCL 管理方面的最大进展是由于对 PTCL 生物学的理解和分类的提高。针对特定亚型的靶向治疗的不断发展对于改善这些疾病患者的长期预后至关重要。
